Determining cancer prognosis

By analyzing specific protein expression levels in exosome samples in lung cancer patients, the problem of invasiveness and applicability of traditional prognostic markers is solved, providing a non-invasive, minimally invasive method to predict disease recurrence in lung cancer patients. and treatment response.

CN118962144APending Publication Date: 2024-11-15COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410716470.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-11-24
Filing Date
2017-11-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to accurately predict disease recurrence and treatment response in lung cancer patients. Traditional prognostic biomarkers require invasive biopsy and are not suitable for some patients, especially patients with comorbidities and many health problems.

Method used

By determining the expression levels of specific proteins in subject exosome samples, such as galactose lectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenosotin C, etc., as markers of cancer prognosis and treatment decision-making , used to evaluate the aggressiveness, prognosis and treatment response of cancer.

Benefits of technology

Provides a non-invasive, minimally invasive approach to assess disease development and treatment response in patients with lung cancer, improving prognostic accuracy and basis for treatment decisions, suitable for most patients, including those not suitable for traditional biopsy .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962144A_ABST
    Figure CN118962144A_ABST
Patent Text Reader

Abstract

Provided herein are methods of determining aggressiveness, prognosis, and response to treatment of cancer, such as non-small cell lung cancer (NSCLC), comprising determining expression levels of one or more differentially expressed protein markers in an exosome sample from a subject. Methods and agents for treating cancer are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application 201780081341.8 (PCT / AU2017 / 051298) with an application date of November 24, 2017 and an invention name of “Determining Cancer Prognosis”. Technical Field

[0002] The present invention relates to cancer. More specifically, the present invention relates to methods of determining the prognosis of cancer, particularly lung cancer. Background Art

[0003] Lung cancer is the leading cause of cancer death and disease burden in many countries. For example, in Australia, lung cancer accounts for 1 in 14 deaths in men and 1 in 25 deaths from any cause in women. Currently, for lung cancer, patients cannot be categorized into responding and non-responding categories.

[0004] Surgery is considered the best treatment for early-stage lung cancer for people who are adequate candidates for surgical resection. Nevertheless, clinical staging is not perfect, as people treated with curative intent still have a significant chance of recurrence. For example, in stage I, II, or IIIA non-small cell lung cancer (NSCLC), approximately 40% to 50% of patients with stage IB NSCLC, 55% to 70% of patients with stage II NSCLC, and an even greater percentage of patients with stage IIIA NSCLC will eventually have their disease relapse and die despite potentially curative surgery. Recently, more active platinum-based combinations and several large clinical trials demonstrating the effectiveness of adjuvant chemotherapy for resected NSCLC have led to the use of adjuvant chemotherapy to improve outcomes for patients with completely resected NSCLC.

[0005] Currently, pathological (TNM) stage is the most important prognostic factor in determining the likelihood of lung cancer recurrence. Genomic biomarkers have been studied for their potential prognostic value. 3-5 , but unlike breast cancer, no biomarkers are routinely used clinically at this time, where FDA-approved tests are increasingly being used on patients (e.g., OncotypeDX). Similarly, other biomarkers including protein expression and proteomics have been proposed for lung cancer, but they are not yet routinely used clinically.

[0006] Therefore, there remains a pressing need for accurate prognostic biomarkers after treatment with curative intent, as a substantial proportion of NSCLC patients, an apparently curable lung cancer, will eventually relapse and relapse after undergoing complete resection or chemoradiation as primary treatment. Prognostic factors are needed to guide clinicians in determining which patients are likely to benefit from adjuvant chemotherapy and who will suffer from potential chemotherapy-related adverse effects without any benefit.

[0007] In addition to the above, traditional validated prognostic biomarkers usually require invasive biopsies. However, in NSCLC patients, comorbidities and general health issues make 20% of patients unsuitable for such biopsies. In addition, the biopsy itself may cause damage and inflammation, increasing morbidity and mortality in NSCLC patients. Therefore, there is a need for an improved method of evaluating patient outcomes with minimally invasive sampling (e.g., blood tests). Summary of the invention

[0008] The present invention broadly relates to determining the expression level of one or more exosome proteins as a prognostic marker for the development of cancer in a subject. In some aspects, the present invention also broadly relates to using such exosome proteins to treat cancer to inform treatment selection or decision making. In a specific form, the cancer is lung cancer, such as non-small cell lung cancer.

[0009] In a first aspect, the present invention provides a method for determining the aggressiveness of cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers comprise one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or correlates with the aggressiveness level of the cancer.

[0010] In a second aspect, the present invention provides a method for determining the prognosis of cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or correlates with a less favorable or more favorable prognosis of the cancer.

[0011] In one embodiment of the method of the above aspects, a relatively decreased expression level of the one or more markers indicates or is associated with a more favorable prognosis and / or a less aggressive cancer; and / or a relatively increased expression level of the one or more markers indicates or is associated with a more unfavorable prognosis and / or a highly aggressive cancer.

[0012] Suitably, the methods of the first and second aspects further comprise the step of diagnosing the subject with: (i) a highly aggressive cancer or a less aggressive cancer; and / or (ii) a less favourable prognosis or a more favourable prognosis.

[0013] In one embodiment of the method of the aforementioned aspects, cancer prognosis or aggressiveness is used at least in part to determine the likelihood of cancer metastasis in the subject. Suitably, a relatively reduced expression level of the one or more markers indicates or is associated with a reduced likelihood of cancer metastasis; and / or a relatively increased expression level of the one or more markers indicates or is associated with an increased likelihood of cancer metastasis.

[0014] In a third aspect, the present invention provides a method for predicting the responsiveness of cancer to an anti-cancer therapy in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers comprise one or more of those proteins listed in Table 1 and / or Table 2, and the altered or modulated expression level of the one or more markers indicates or is associated with a relative increased or decreased responsiveness of the cancer to the anti-cancer therapy.

[0015] In relation to the first, second and third aspects of the invention, the method suitably comprises the further step of treating cancer in the subject.

[0016] In a fourth aspect, the present invention provides a method for treating cancer in a subject, the method comprising the steps of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and based on the determination made, starting, continuing, changing or interrupting anti-cancer therapy.

[0017] Suitably, for the methods of the third and fourth aspects, the anti-cancer treatment comprises administering to the subject a therapeutically effective amount of an anti-cancer agent that reduces the expression and / or activity of said one or more markers.

[0018] In one embodiment of the methods of the third and fourth aspects, the anti-cancer treatment comprises administering to the subject a therapeutically effective amount of an anti-cancer agent that prevents or inhibits metastasis of said cancer.

[0019] With regard to the methods of the third and fourth aspects, the anti-cancer agent is suitably an antibody or a small molecule (eg, a small organic or inorganic molecule antagonist).

[0020] Suitably, the method of the preceding aspects further comprises the step of obtaining an exosome sample from the subject.

[0021] With respect to the methods of the aforementioned aspects, the one or more markers are suitably selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof. In a specific embodiment, the one or more markers are selected from the group consisting of galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

[0022] Suitably, the method of the preceding aspects further comprises the step of comparing the expression level of the one or more markers in the exosome sample with a reference exosome expression level of the corresponding one or more markers.

[0023] In a fifth aspect, the present invention provides a method of identifying or producing an agent for treating cancer in a subject, comprising the steps of:

[0024] (a) contacting cells expressing markers listed in Table 1 and / or Table 2 with a candidate agent; and

[0025] (b) determining whether the candidate agent modulates the expression and / or activity of the marker.

[0026] In certain embodiments, the candidate agent at least partially reduces, eliminates, suppresses or inhibits the expression and / or activity of a marker.

[0027] Suitably, the cancer of the aforementioned aspects is or comprises lung cancer. Preferably, lung cancer comprises squamous cell carcinoma, adenocarcinoma, large cell carcinoma, small cell carcinoma and mesothelioma. Even more preferably, lung cancer is non-small cell lung cancer.

[0028] Suitably, the subject of the above aspects is a mammal, preferably a human.

[0029] Unless the context requires otherwise, the terms “comprise”, “comprises”, “comprising” or similar terms are intended to represent a non-exclusive inclusion such that a recited list of elements or features does not include only those stated or recited elements but may include other elements or features that are not listed or recited.

[0030] The indefinite articles "a" and "an" are used herein to indicate or cover a single or a plurality of elements or features, and should not be considered to indicate or define "one" or "single" element or feature. For example, "a" cell includes one cell, one or more cells, and a plurality of cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 .Exosomes are secreted by NSCLC cells. A Protein characterization of exosomes demonstrated the presence of exosomal markers and the absence of non-exosomal calnexin. B Exosomes secreted by NSCLC have the expected size distribution. C Hypoxia increases exosome secretion but does not change the exosome size range. D Hypoxia significantly increases exosome secretion by NSCLC cells. CL: cell lysate; E: exosome lysate.

[0032] Figure 2 .Hypoxia alters exosome content. Exosomes were harvested from conditioned media from cells cultured for 24 h under normoxic (21% O2) or hypoxic (2% O2) conditions. A Scanning electron microscopy shows classic exosome morphology. B Quantitative mass spectrometry shows 55 proteins commonly upregulated under hypoxic conditions, n=5, FDR 1%. C, D Validation of protein targets by Western blotting and ELISA.

[0033] Figure 3 .Upregulated proteins are associated with patient disease progression. A Exosomes isolated from NSCLC patients show the expected size range and morphology. B, C Hypoxia protein markers identified in vitro are upregulated in patients who relapse within the first 18 months. D ROC curve of combined protein signatures (GANAB, VCP and galectin-3-binding protein) is used to identify patients who relapse within 12 months. E Patients' disease-free survival is associated with their exosome content. Patients with at least 2 of the above highly expressed markers progress rapidly compared to patients who express only one marker or no marker in their exosomes.

[0034] Figure 4 Other upregulated proteins identified in hypoxic exosomes have prognostic value. TNC is upregulated under hypoxic conditions and is more abundant in exosomes from patients with rapidly progressing NSCLC.

[0035] Figure 5. Individual ROC and survival curves for the proteins used in patient signatures.

[0036] Figure 6 .Hypoxia-induced changes in the protein composition of NSCLC cell-derived exosomes. a, The morphology of isolated exosomes was assessed using transmission electron microscopy. Images of normoxic and hypoxic SKMES1-derived exosomes (size bar 200 nm) also demonstrate a clear upregulation of exosome concentrations. b, Nanoparticle analysis using TRPS of exosomes isolated from 4 different NSCLC cell lines demonstrated that most exosomes had a size range of 30 to 150 nm. c, Quantitative mass spectrometry identified 32 proteins that were commonly upregulated in H358 and SKMES1 exosomes (FDR < 0.1%; n = 5). d, e, Mass spectrometry results were confirmed using Western blot analysis for VCP (FLOT1 was used as a loading control) and ELISA for MAC2BP, TNC, PSMA2, and THBS1 in H358, SKMES1, H23, and H1975 NSCLC cell lines (●–H358, ■–SKMES1, ▲–H23, ◆–H1975). *p<0.05, **p<0.01.

[0037] Figure 7 .Hypoxic exosome signature predicts disease progression in NSCLC patients. a, b, Exosomes can be isolated from NSCLC plasma based on morphology as shown by TEM (size bar 200 nm) and size distribution of 20-150 nm. c, TRPS demonstrated no difference in exosome concentration in plasma of healthy controls or patients who progressed within 18 months or patients who did not relapse within 18 months. d, Exosomes isolated from NSCLC patients showed enrichment of VCP in patients who progressed within 18 months compared to patients who did not relapse and healthy controls (FLOT1 was used as a loading control). e, Hypoxic exosome signature was upregulated in exosomes derived from patients who progressed within 18 months. f, The number of hypoxic protein markers exceeding the Youden Index threshold confirmed a clear distinction between patients who progressed within 18 months or patients who did not relapse within 18 months. g, Kaplan-Meier shows a clear distinction in patient DFS based on the abundance of proteins from the hypoxic exosome signature (≥3 markers exceeding the Youden Index value). h, ROC curve confirmed that hypoxic exosome signature is a perfect prognostic marker for disease progression (<18 months) in NSCLC patients, while exosome concentration has no prognostic value. i, Kaplan-Meier curve confirmed that hypoxic exosome signature is also associated with overall survival in NSCLC patients.

[0038] Figure 8.Hypoxic exosome signatures are derived from lung cells that have undergone EMT. a, GSEA confirmed that the signature epithelial to mesenchymal transition gene set was significantly associated with exosomes derived from hypoxic NSCLC cells. b, Normal lung epithelial cells (30KT) and transformed lung mesenchymal cells (30KT p53 / KRAS / LKB1 ), which demonstrates the oncogenic-induced phenotypic shift to a mesenchymal phenotype. c, Western blot in cell lysates confirms that at 30KT p53 / KRAS / LKB1 Loss of epithelial marker E-cadherin and gain of mesenchymal marker vimentin in cells. d, Cells derived from epithelial (30KT) and mesenchymal (30KT p53 / KRAS / LKB1 ) Western blot of VCP in exosomes from lung cells (CD9 was used as a loading control). e, exosomes from epithelial (30KT) and mesenchymal (30KT p53 / KRAS / LKB1 ) ELISA of MAC2BP, TNC, PSMA2, and THBS1 in exosomes of lung cells. *p<0.05, **p<0.01, ***p<0.001. f, Immunohistochemistry of primary tumors demonstrated that loss of E-cadherin expression was associated with patients classified as high marker group (≥3 markers exceeding Youden Index value).

[0039] Fig. 9 .Confirmation of hypoxic exosome signatures for predicting disease recurrence in NSCLC patients. a, b, 2 patients (confirmation group) followed at the indicated points in c 18 F-FDG PET / CT images. c, Supporting the discovery group, the exosome concentrations in patients who relapsed within 18 months were similar compared to those who relapsed after 18 months, specifically pointing out patients 44 and 53. d, The number of hypoxic protein markers exceeding the Youden index threshold confirmed the clear distinction between patients who progressed within 18 months or those who did not relapse within 18 months. e, Kaplan-Meier plot of DFS of NSCLC patients with low or high abundance of hypoxic exosome proteins indicated a clear distinction in DFS. f, ROC curve analysis again showed a perfect classification of patients who would progress within 18 months. g, Kaplan-Meier plot confirmed that this marker is also a prognostic marker for overall survival of NSCLC patients.

[0040] Fig.10 Hypoxia increases exosome secretion from NSCLC cells. a, Exosomes isolated from NSCLC cell lines expressed classical exosome markers HSP70, FLOT1, and CD63. The cell marker CANX was only present in cell lysates, but not in exosome lysates. b, Hypoxia increases exosome secretion from NSCLC cell lines. n=3±SEM, *p<0.05, **p<0.01, ***p<0.001.

[0041] Fig.11 The discovery group demonstrated that exosomal proteins were associated with disease progression in NSCLC patients. ae, Individual Kaplan-Meier and ROC curves for each protein in the hypoxic exosome signature.

[0042] Fig.12 Gene set enrichment analysis (GSEA) identified gene sets significantly elevated in exosomes derived from hypoxic NSCLC cells. A, Heatmap of proteins identified in the EMT gene set. b, GSEA of the total exosomal protein expression dataset using the signature gene set revealed that hypoxic exosomes were enriched in proteins related to glycolysis, MYC targets, E2F targets, and xenobiotic metabolism (FDR < 0.05). NES-normalized enrichment scores.

[0043] Fig.13 Reduced E-cadherin expression correlates with the number of marker proteins exceeding the Youden index threshold. a, IHC scoring table with reference marker scores. b, Low E-cadherin IHC scores were more strongly associated with patients who relapsed within 18 months.

[0044] Fig.14 Upregulated marker proteins in the confirmed group were associated with DFS. a, Western blot of VCP confirmed upregulation in patients who progressed within 18 months compared to patients who progressed after 18 months (FLOT1 was used as a loading control). b, Individual marker values ​​for patients 44 and 53 showed that patient 53, who progressed within 18 months, had significantly elevated baseline levels of marker proteins compared to patient 44. DETAILED DESCRIPTION

[0045] The present invention is based, at least in part, on the surprising discovery that hypoxia-induced exosomal proteins identified in vitro are accurate prognostic biomarkers for cancer development and aggressiveness in patients.

[0046] In one aspect, the present invention provides a method for determining the aggressiveness of cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or correlates with the aggressiveness level of the cancer.

[0047] In a related aspect, the present invention provides a method of determining the prognosis of a cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or correlates with a less favorable or more favorable prognosis of the cancer.

[0048] With regard to the above aspects, the one or more markers are suitably selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof. In a specific embodiment, the one or more markers are selected from the group consisting of galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

[0049] As generally used herein, unless otherwise indicated, the expression level of one or more of the following may refer to the expression level of the nucleic acid encoding the protein (e.g., RNA, mRNA and cDNA), the protein itself, or both: (a) 55 marker proteins identified as upregulated in Table 1; and (b) 32 marker proteins identified as upregulated in Table 2.

[0050] As generally used herein, the terms "cancer," "tumor," "malignant," and "malignancy" refer to a disease or condition, or cells or tissues associated with a disease or condition, characterized by abnormal or aberrant cell proliferation, differentiation, and / or migration, often accompanied by an abnormal or aberrant molecular phenotype, which includes one or more genetic mutations or other genetic changes associated with tumorigenesis, expression of tumor markers, loss of expression or activity of tumor suppressors, and / or abnormal or aberrant expression of cell surface markers.

[0051] "Aggressive" and "aggressive" refer to the property or tendency of a cancer to have a relatively poor prognosis due to one or more of a combination of characteristics or factors, including, but not limited to: at least partial resistance to therapies available for the treatment of the cancer; invasiveness; likelihood of metastasis; recurrence after treatment; and low likelihood of patient survival.

[0052] In specific embodiments, the proteins provided herein (e.g., proteins provided in Tables 1 and 2) are prognostic for aggressive disease, particularly shorter pathological recurrence time and / or shorter patient survival time. In other embodiments, the proteins provided herein (e.g., proteins provided in Tables 1 and 2) are associated with or indicate metastatic cancer, more specifically metastatic NSCLC. In this regard, it is apparent that many of the 32 proteins provided in Table 2 are also listed in Table 1, except, for example, LTBP3.

[0053] Cancer may include any aggressive or potentially aggressive cancer, tumor, or other malignancy, such as listed in the NCI Cancer Index at http: / / www.cancer.gov / cancertopics / alphalist, including all major cancer forms, such as sarcomas, carcinomas, lymphomas, leukemias, and blastomas, but not limited thereto. These cancers may include, but are not limited to, breast cancer, lung cancer (including lung adenocarcinoma and mesothelioma), reproductive system cancers (including ovarian cancer, cervical cancer, uterine cancer, and prostate cancer), brain and nervous system cancers, head and neck cancers, gastrointestinal cancers (including colon cancer, colorectal cancer, and gastric cancer), liver cancer, kidney cancer, skin cancers (such as melanoma and skin cancer), blood cell cancers (including lymphoma and myelomonocytic cancer), endocrine system cancers (such as pancreatic cancer and pituitary cancer), musculoskeletal cancers (including bone cancer and soft tissue cancer).

[0054] In a specific embodiment, the cancer comprises breast cancer, lung cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, brain and nervous system cancer, head and neck cancer, colon cancer, colorectal cancer, stomach cancer, liver cancer, kidney cancer, bladder cancer, skin cancer, pancreatic cancer, pituitary cancer or adrenal cancer. More preferably, the cancer is or comprises lung cancer, such as NSCLC.

[0055] In specific embodiments, the cancer of the aspects disclosed herein is or comprises lung cancer. To this end, it is apparent that lung cancer may include any invasive lung cancer and cancer subtypes known in the art, such as non-small cell carcinoma (i.e., squamous cell carcinoma, adenocarcinoma, and large cell carcinoma), small cell carcinoma, and mesothelioma. In a preferred embodiment, lung cancer is or comprises non-small cell lung cancer (NSCLC).

[0056] The terms "prognosis" and "prognostic" are used herein to include prognosis, which can predict clinical outcomes (with or without medical treatment), select an appropriate course of treatment (or whether the treatment is effective), and / or monitor current treatment and possibly change treatment. This can be based at least in part on determining the gene and / or protein expression levels of one or more markers by the methods of the present invention, which can be combined with determining the expression levels of additional proteins and / or other nucleic acid biomarkers. Prognosis can also include predicting, foreseeing, or forecasting any lasting or permanent physical or psychological effects of cancer suffered by the subject after the cancer is successfully treated or otherwise resolved. In addition, prognosis can include one or more of the following: determining the possibility or occurrence of metastasis, determining treatment responsiveness, implementing appropriate treatment regimens, determining the probability, possibility, or potential of cancer recurrence after treatment, and predicting the development of resistance to established therapies (e.g., chemotherapy). It should be understood that a positive prognosis typically refers to a beneficial clinical outcome or prospect, such as long-term survival without a subject's cancer recurrence, while a negative prognosis typically refers to a negative clinical outcome or prospect, such as cancer recurrence or development.

[0057] In one embodiment of the method of the aforementioned two aspects, a relatively decreased expression level of the one or more markers indicates or is associated with a more favorable prognosis and / or a less aggressive cancer; and / or a relatively increased expression level of the one or more markers indicates or is associated with a more unfavorable prognosis and / or a highly aggressive cancer.

[0058] In a specific embodiment, cancer prognosis or aggressiveness is used, at least in part, to determine the likelihood of cancer metastasis in said subject.

[0059] As used herein, "metastasis" or "metastatic" refers to the migration or metastasis of a malignant cell or tumor via the circulatory or lymphatic systems or via a natural body cavity, typically from a primary focus of a tumor, cancer or neoplasia to a distant site in the body, and the subsequent development of one or more secondary tumors or colonies thereof at one or more new locations. "Metastasis" refers to a secondary tumor or colony formed as a result of metastasis, and encompasses micrometastasis as well as regional (including lymph node) and distant metastasis.

[0060] Suitably, a relatively decreased expression level of the one or more markers indicates or is associated with a decreased likelihood of the cancer metastasizing; and / or a relatively increased expression level of the one or more markers indicates or is associated with an increased likelihood of the cancer metastasizing.

[0061] In one embodiment, cancer prognosis or aggressiveness is used, at least in part, to determine whether a subject will benefit from treatment of the cancer. For example, patients with a favorable prognosis and / or a less aggressive cancer are less likely to suffer from rapid local development of cancer and / or metastasis and may be exempted from more invasive monitoring and / or treatment.

[0062] In another embodiment, cancer prognosis or aggressiveness is used, at least in part, to formulate a treatment strategy for a subject.

[0063] In one embodiment, cancer prognosis or aggressiveness is used, at least in part, to determine disease progression or recurrence in a subject.

[0064] In one embodiment, cancer prognosis or aggressiveness is used, at least in part, to determine estimated survival time.

[0065] For purposes of the present invention, "isolated" refers to material that has been removed from its natural state or otherwise subjected to artificial manipulation. An isolated material may be substantially or essentially free of components that normally accompany it in its natural state, or may be manipulated so as to be in an artificial state with components that normally accompany it in its natural state. An isolated material may be in natural, chemically synthesized, or recombinant form.

[0066] As used herein, "gene" is a nucleic acid that is a structural hereditary unit of a genome, which may include one or more nucleotide sequences encoding amino acids and one or more non-coding nucleotide sequences, including, but not limited to, promoters and other 5' non-translated sequences, introns, polyadenylation sequences and other 3' non-translated sequences. In most cellular organisms, a gene is a nucleic acid comprising double-stranded DNA.

[0067] As used herein, the term "nucleic acid" refers to single-stranded or double-stranded DNA and RNA. DNA includes genomic DNA and cDNA. RNA includes mRNA, RNA, RNAi, siRNA, cRNA and autocatalytic RNA. Nucleic acid can also be a DNA-RNA hybrid. Nucleic acid comprises a nucleotide sequence, which typically includes nucleotides containing A, G, C, T or U bases. However, the nucleotide sequence may include other bases, such as inosine, methylcytosine, methylinosine, methyladenosine and / or thiouridine, but is not limited thereto.

[0068] Also included are "variant" nucleic acids, which include nucleic acids comprising naturally occurring (e.g., alleles) variants and nucleotide sequences of straight homologs (e.g., from different species) of nucleic acids encoding one or more markers provided herein, respectively. Preferably, nucleic acid variants have at least 70% or 75%, preferably at least 80% or 85%, or more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the nucleotide sequences disclosed herein.

[0069] Also included are nucleic acid fragments. A "fragment" is a segment, domain, part or region of a nucleic acid that constitutes less than 100% of the nucleotide sequence, respectively. Non-limiting examples are amplification products or primers or probes. In specific embodiments, a nucleic acid fragment can comprise, for example, at least 10, 15, 20, 25, 30 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, and 7500 contiguous nucleotides of the nucleic acid.

[0070] As used herein, a "polynucleotide" is a nucleic acid having eighty (80) or more consecutive nucleotides, while an "oligonucleotide" has fewer than eighty (80) consecutive nucleotides. A "probe" can be a single-stranded or double-stranded oligonucleotide or polynucleotide, suitably labeled, for example, for detection of complementary sequences in an Northern or Southern blot. A "primer" is typically a single-stranded oligonucleotide preferably having 15-50 consecutive nucleotides, which is capable of bonding to a complementary nucleic acid "template" and being cleaved by a DNA polymerase (e.g., Taq polymerase, RNA-dependent DNA polymerase, or Sequenase TM ) in a template-dependent manner. A "template" nucleic acid is a nucleic acid that undergoes nucleic acid amplification.

[0071] "Protein" refers to a polymer of amino acids. As is well known in the art, amino acids can be natural or unnatural amino acids, D-amino acids or L-amino acids. As will be appreciated by those skilled in the art, the term "protein" also includes within its scope phosphorylated forms of proteins (i.e., phosphoproteins) and / or glycosylated forms of proteins (i.e., glycoproteins). A "peptide" is a protein having no more than fifty (50) amino acids. A "polypeptide" is a protein having more than fifty (50) amino acids.

[0072] Also provided are protein "variants", such as naturally occurring variants (e.g., allelic variants) and orthologs or isoforms of one or more markers provided herein, such as those listed in Tables 1 and 2. Preferably, the protein variants have at least 70% or 75%, preferably at least 80% or 85%, or more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence of one or more markers disclosed herein or known in the art. To this end, Tables 1 and 2 also include accession numbers for examples of protein sequences related to the protein markers, as are well known in the art and incorporated herein by reference.

[0073] , 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, and 1200 consecutive amino acids of the protein.

[0074] It will be appreciated by those skilled in the art that exosomes are small (i.e., typically 30-150 nm) cell-derived membrane vesicles of endocytic origin. They may contain lipids, nucleic acids, and proteins, and are released into the extracellular environment after fusion with the plasma membrane. Typically, exosomes are characterized by the presence of marker proteins (including CD63, CD9, HSP70, lipid valve structural protein 1, and TSG101) as well as their morphology and size.

[0075] According to the methods of the present invention, an exosome sample containing one or more exosomes may contain or be obtained from most biological fluids, including but not limited to blood, serum, plasma, ascites, cystic fluid, pleural fluid, peritoneal fluid, cerebrospinal fluid, tears, urine, saliva, sputum, nipple aspirates, lymph fluid, fluids of the respiratory, intestinal and urogenital tracts, breast milk, intra-organ systemic fluids or combinations thereof. To this end, the exosome sample may be isolated or purified from a biological fluid or sample (such as those provided above) to facilitate the removal of contaminating proteins, lipoproteins, etc.

[0076] To this end, exosomes or exosome samples can be isolated by any method known in the art, such as, but not limited to, ultracentrifugation, size exclusion chromatography, exosome precipitation (e.g., ExoQuick from System Biosciences), affinity-based capture of exosomes (e.g., affinity purification with antibodies against CD63, CD81, CD82, CD9, Alix, Annexin, EpCAM, and Rab5), and any combination thereof.

[0077] As will be appreciated by those skilled in the art, compared to the expression level in a control or reference sample, or compared to a threshold expression level, the gene and / or protein expression level of one or more proteins provided herein may be relatively (i) higher, increased or greater; or (ii) lower, reduced or reduced. In one embodiment, if the expression level exceeds the average and / or median expression level of a reference population, the expression level may be classified as higher, increased or greater. In one embodiment, if the expression level is less than the average and / or median expression level of a reference population, the expression level may be classified as lower, reduced or reduced. In this regard, a reference population may be a subject group having the same cancer type, subgroup, stage and / or grade as the mammal determining the expression level.

[0078] As used herein, terms such as "higher", "increased" and "greater" refer to an elevated amount or level of nucleic acid and / or protein (e.g., in an exosome sample) compared to a control or reference level or amount. The expression level of nucleic acid and / or protein of one or more markers may be relative or absolute. In some embodiments, if the expression level of one or more markers is about 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, 400%, or at least about 500% higher than the gene and / or protein expression level of the corresponding or corresponding protein of the control or reference level or amount, the gene and / or protein expression of one or more markers is higher, increased or greater.

[0079] As used herein, the terms "lower", "reduced" and "reduced" refer to a lower amount or level of nucleic acid and / or protein (e.g., in an exosome sample) compared to a control or reference level or amount. The expression level of nucleic acid and / or protein of one or more markers provided herein may be relative or absolute. In some embodiments, if the expression level of one or more markers is less than about 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% or 10% of the gene and / or protein expression level or amount of the corresponding or corresponding protein of the control or reference level or amount, or even less than about 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%, then the gene and / or protein expression of one or more markers is lower, reduced or reduced.

[0080] The term "control sample" typically refers to a biological sample, such as an exosome sample, from a (healthy) non-diseased individual who does not have cancer. In one embodiment, the control sample can be from a subject known to be free of cancer or a sample obtained from a subject at an earlier time point. Alternatively, the control sample can be from a subject in remission of cancer. The control sample can be a combined sample, an average sample, or a single sample. An internal control is a marker from the same biological sample (e.g., an exosome sample) tested.

[0081] As used herein, gene and / or protein expression levels can be their absolute or relative amounts. Therefore, in some embodiments, the gene and / or protein expression levels of one or more markers provided herein are compared with control expression levels (e.g., gene and / or protein expression levels of one or more "housekeeping" genes and / or proteins in an exosome sample of a subject).

[0082] In other embodiments, the gene and / or protein expression level of one or more markers is compared to a threshold expression level (e.g., gene and / or protein expression level in an exosome sample). The threshold expression level is typically a quantified level of gene and / or protein expression of one or more markers of the present invention. Typically, gene and / or protein expression levels of one or more markers in an exosome sample that exceed or fall below a threshold expression level can predict a specific disease state or outcome. The nature and value of the threshold expression level (if any) typically vary based on the method selected for determining the expression of one or more genes or their products, which are used to determine, for example, prognosis and / or response to anticancer therapy in a subject.

[0083] Those skilled in the art can determine the threshold level of gene and / or protein expression in the exosome sample using any method known in the art for measuring gene or protein expression (such as those described herein), which can be used to determine, for example, prognosis and / or response to anticancer therapy. In one embodiment, the threshold level is the average and / or median gene and / or protein expression level (median or absolute value) of one or more markers in a reference population, and the reference population, for example, has the same cancer type, subgroup, stage and / or grade as the subject for which the expression level is determined. In addition, the concept of threshold expression level should not be limited to a single value or result. In this regard, the threshold expression level can encompass multiple threshold expression levels, which can represent, for example, a high, medium or low probability of metastasis of a subject's cancer.

[0084] In one embodiment, the lower gene and / or protein expression levels of one or more markers provided herein indicate or are associated with a relatively increased responsiveness of a cancer to an anticancer treatment. In alternative embodiments, the lower gene and / or protein expression levels of one or more markers provided herein indicate or are associated with a relatively reduced responsiveness of a cancer to an anticancer treatment.

[0085] The terms "determine," "measure," "evaluate," "assess," and "measure" are used interchangeably herein and may include any form of measurement known in the art, such as those described below.

[0086] Determine, assess, evaluate, measure or measure the corresponding nucleic acid (such as RNA, mRNA and cDNA) of one or more markers provided herein can be carried out by any technology known in the art.These can be the technology including nucleic acid sequence amplification, nucleic acid hybridization, nucleotide sequencing, mass spectrometry and any combination of these.

[0087] Nucleic acid amplification techniques typically include repeated cycles of attaching one or more primers to a "template" nucleotide sequence under appropriate conditions and using a polymerase to synthesize a nucleotide sequence complementary to the target, thereby "amplifying" the target nucleotide sequence. Nucleic acid amplification techniques are well known to those skilled in the art and include, but are not limited to, polymerase chain reaction (PCR); strand displacement amplification (SDA); rolling circle replication (RCR); nucleic acid sequence-based amplification (NASBA), Q-β replicase amplification; helicase-dependent amplification (HAD); loop-mediated isothermal amplification (LAMP); nickase amplification reaction (NEAR) and recombinase polymerase amplification (RPA), but are not limited thereto. As generally used herein, "amplification product" refers to a nucleic acid product produced by a nucleic acid amplification technique.

[0088] PCR includes quantitative and semiquantitative PCR, real-time PCR, allele-specific PCR, methylation-specific PCR, asymmetric PCR, nested PCR, multiplex PCR, touch-down PCR, digital PCR, and other variations and modifications to "basic" PCR amplification.

[0089] Nucleic acid amplification techniques can be performed using DNA or RNA extracted, isolated or otherwise obtained from a cell or tissue source. In other embodiments, nucleic acid amplification can be performed directly on a cell or tissue sample that has been appropriately treated.

[0090] Nucleic acid hybridization typically involves hybridizing a nucleotide sequence (typically in the form of a probe) to a target nucleotide sequence under appropriate conditions, whereby the hybridized probe-target nucleotide sequence is subsequently detected. Non-limiting examples include, but are not limited to, Northern blots, slot blots, in situ hybridization, and fluorescence resonance energy transfer (FRET) detection. Nucleic acid hybridization can be performed using DNA or RNA extracted, isolated, amplified, or otherwise obtained from a cell or tissue source, or directly on a suitably treated cell or tissue sample.

[0091] It will also be appreciated that a combination of nucleic acid amplification and nucleic acid hybridization may be used.

[0092] Determining, assessing, evaluating, determining or measuring the protein level of one or more exosome proteins can be performed by any technique known in the art that is capable of detecting these proteins, whether expressed on the surface or inside the exosomes, or proteins isolated, extracted or otherwise obtained from an exosome sample of a subject. These techniques include antibody-based detection using one or more antibodies that bind to the protein, electrophoresis, isoelectric focusing, protein sequencing, chromatography techniques and mass spectrometry and combinations thereof, but are not limited thereto. Antibody-based detection may include flow cytometry, ELISA, immunoblotting, immunoprecipitation, radioimmunoassay (RIA) and immunocytochemistry using fluorescently labeled antibodies, but are not limited thereto.

[0093] It should be understood that determining the expression of one or more markers provided herein may include determining both nucleic acid levels thereof (e.g., by nucleic acid amplification and / or nucleic acid hybridization) and protein levels thereof. Thus, detecting and / or measuring the expression of one or more markers of an exosome sample from a subject may be performed by any of those methods described herein or a combination thereof (e.g., measuring mRNA levels or amplified cDNA copies thereof and / or by measuring protein products thereof), but is not limited thereto.

[0094] In view of the foregoing, it is also understood that the expression level of one or more markers provided herein can be an absolute or relative amount of an expressed gene or its gene product (nucleic acids, including, for example, RNA, mRNA and cDNA, and / or protein).

[0095] Suitably, the method of the above aspects further comprises the step of diagnosing the subject as having: (i) a highly aggressive cancer or a less aggressive cancer; and / or (ii) a less favourable prognosis or a more favourable prognosis.

[0096] In another aspect, the present invention provides a method for predicting the responsiveness of cancer to an anti-cancer therapy in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers comprise one or more of those proteins listed in Table 1 and / or Table 2, and the altered or modulated expression level of the one or more markers indicates or correlates with a relative increased or decreased responsiveness of the cancer to the anti-cancer therapy.

[0097] As will be appreciated by those skilled in the art, when compared to a control or reference sample or expression level (e.g., threshold level), the expression level of a gene or protein may be considered to be "changed" or "regulated". In one embodiment, if the expression level is greater than the average and / or median relative expression level of a reference population, the expression level may be classified as a high level, and if the expression level is less than the average and / or median expression level of a reference population, the expression level may be classified as a low level. In this regard, a reference population may be a subject group having the same cancer type, subgroup, stage, and / or grade as the mammal determining the expression level. In addition, the expression level may be relative or absolute.

[0098] Suitably, the one or more markers are selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof. In a specific embodiment, the one or more markers are selected from the group consisting of galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

[0099] In one embodiment, the higher expression level of the one or more markers indicates or is associated with a relatively increased responsiveness of the cancer to an anticancer treatment. In alternative embodiments, the higher expression level of the one or more markers indicates or is associated with a relatively decreased responsiveness of the cancer to an anticancer treatment.

[0100] With respect to the invention of the preceding aspects, the method suitably comprises the further step of treating cancer in the subject.

[0101] Other aspects of the invention relate to the treatment of cancer in a subject.

[0102] In a specific aspect, cancer treatment is performed in conjunction with the following steps: determining the expression level of one or more markers in an exosome sample of a subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and based on the decision made, initiating, continuing, changing or interrupting cancer treatment.

[0103] Suitably, the one or more markers are selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof. In a specific embodiment, the one or more markers are selected from the group consisting of galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

[0104] In this regard, it should be understood that those methods described herein for predicting the responsiveness of cancer to anticancer agents can further include administering a therapeutically effective amount of an anticancer treatment such as an anticancer agent to a mammal. In a preferred embodiment, when the gene and / or protein expression levels of one or more markers described herein indicate that the cancer is relatively responsive to an anticancer agent or is associated with it, anticancer treatment is administered.

[0105] Suitably, one or more medicaments are administered to a subject as a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient. In this regard, any dosage form and route of administration (such as those provided therein) can be used to provide the compositions of the present invention to a subject.

[0106] Cancer treatment can include drug therapy (e.g., small organic or inorganic molecules), chemotherapy, antibodies, nucleic acid and other biomolecular therapies, radiotherapy, surgery, nutritional therapy, relaxation or mediation therapy and other natural or holistic therapies, but is not limited thereto. Typically, drugs (e.g., small organic or inorganic molecules), biomolecules (e.g., antibodies, inhibitory nucleic acids, such as siRNA) or chemotherapeutic agents are referred to herein as "anti-cancer therapeutic agents" or "anti-cancer agents."

[0107] Methods for treating cancer can be preventive, prophylactic or therapeutic, and are suitable for treating cancer in mammals, particularly humans. As used herein, "treating", "treat" or "treatment" refers to a therapeutic intervention, course of action or regimen that at least improves cancer symptoms after cancer and / or its symptoms have at least begun to appear. As used herein, "preventing", "prevent" or "prevention" refers to a therapeutic intervention, course of action or regimen that begins before the onset of cancer and / or cancer symptoms in order to prevent, inhibit or delay the development or progression of cancer or symptoms.

[0108] The term "therapeutically effective amount" describes the amount of a given agent that is sufficient to achieve a desired effect in a subject treated with the agent. For example, this can be the amount of a chemotherapeutic agent necessary to reduce, alleviate and / or prevent cancer or a cancer-related disease, disorder or condition. In some embodiments, a "therapeutically effective amount" is sufficient to reduce or eliminate the symptoms of cancer. In other embodiments, a "therapeutically effective amount" is an amount sufficient to achieve a desired biological effect, such as an amount that effectively reduces or prevents cancer growth and / or metastasis.

[0109] Ideally, a therapeutically effective amount of an agent is an amount sufficient to induce the desired result without causing substantial cytotoxic effects in a subject. The effective amount of an agent for reducing, alleviating and / or preventing cancer will depend on the subject being treated, the type and severity of any associated disease, disorder and / or condition (e.g., the number and location of any associated metastases), and the mode of administration of the therapeutic composition.

[0110] Suitably, the anti-cancer therapeutic is administered to a mammal in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient.

[0111] "Pharmaceutically acceptable carrier, diluent or excipient" refers to a solid or liquid filler, diluent or encapsulating material that can be safely used for systemic administration. Depending on the specific route of administration, various carriers well known in the art can be used. These carriers can be selected from the group consisting of sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, liposomes and other lipid-based carriers, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline and salts (e.g., inorganic acid salts, including hydrochlorides, bromides and sulfates, organic acids, such as acetates, propionates and malonates) and pyrogen-free water.

[0112] A useful reference describing pharmaceutically acceptable carriers, diluents, and excipients is Remington's Pharmaceutical Sciences (Mack Publishing Co. NJ USA, 1991), which is incorporated herein by reference.

[0113] Any safe route of administration can be used to provide the composition of the present invention to the patient. For example, oral, rectal, parenteral, sublingual, buccal, intravenous, intraarticular, intramuscular, intradermal, subcutaneous, inhalation, intraocular, intraperitoneal, intracerebroventricular, transdermal routes, etc. can be used. Intramuscular and subcutaneous injections are suitable, for example, for administering immunotherapeutic compositions, protein vaccines, and nucleic acid vaccines.

[0114] Dosage forms include tablets, dispersants, suspensions, injections, solutions, syrups, lozenges, capsules, suppositories, aerosols, transdermal patches, etc. These dosage forms may also include injection or implantation of controlled release devices designed specifically for this purpose or other forms of implants modified to function in this manner. The controlled release of the therapeutic agent may be achieved, for example, by coating the therapeutic agent with a hydrophobic polymer, including acrylic resins, waxes, higher fatty alcohols, polylactic acid and polyglycolic acid, and certain cellulose derivatives such as hydroxypropyl methylcellulose. In addition, controlled release may be achieved by using other polymer matrices, liposomes, and / or microspheres.

[0115] Compositions of the invention suitable for oral or parenteral administration can be provided as discrete units (e.g., capsules, sachets or tablets, each containing a predetermined amount of one or more therapeutic agents of the invention), as powders or granules, or as solutions or suspensions in aqueous liquids, non-aqueous liquids, oil-in-water emulsions or water-in-oil liquid emulsions. Such compositions can be prepared by any pharmaceutical method, but all methods include the step of combining one or more medicaments as described above with a carrier constituting one or more essential ingredients. Typically, the composition is prepared by uniformly and intimately mixing the medicament of the invention with a liquid carrier or a finely divided solid carrier or both, and then molding the product into a desired form if necessary.

[0116] The above-mentioned compositions can be administered in a manner compatible with the dosage formulation and in a pharmaceutically effective amount. In the context of the present invention, the dosage administered to the subject should be sufficient to achieve a beneficial response in the subject within an appropriate time period. The amount of the medicament to be administered may depend on the subject to be treated, including its age, sex, weight and general health, and these factors will depend on the judgment of the practitioner.

[0117] In specific embodiments, anti-cancer treatments and / or agents may be directed to inhibiting the action and / or reducing the expression of one or more markers.

[0118] In other embodiments, anti-cancer treatments and / or agents may be directed to preventing or inhibiting metastasis of cancer.

[0119] In alternative embodiments, anti-cancer treatments and / or agents may be directed to genes or gene products other than one or more markers of the invention. For example, anti-cancer treatments may target genes or gene products that are known to interact directly or indirectly with one or more markers.

[0120] In a specific embodiment, the present invention provides a "companion diagnostic" for cancer treatment, wherein the expression level of one or more markers of the present invention provides information to clinicians and the like, which is used for the safe and / or effective administration of the cancer treatment.

[0121] Suitably, the cancer is of the type described above, but is not limited thereto.

[0122] With reference to the preceding aspects, the method suitably comprises an initial step of obtaining an exosome sample from a subject, for example from a biological sample and / or isolation method such as those described above.

[0123] In another aspect, the present invention provides a method of identifying or producing an agent for treating cancer in a subject, comprising the steps of:

[0124] (a) contacting cells expressing markers listed in Table 1 and / or Table 2 with a candidate agent; and

[0125] (b) determining whether the candidate agent modulates the expression and / or activity of the marker.

[0126] In certain embodiments, the candidate agent at least partially reduces, eliminates, suppresses or inhibits the expression and / or activity of a marker.

[0127] Suitably, the agent has or displays few or no significant off-target and / or non-specific effects.

[0128] Preferably, the agent is an antibody or a small molecule.

[0129] Suitably, the marker is selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof. In a specific embodiment, the one or more markers are selected from the group consisting of galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

[0130] In embodiments relating to antibody inhibitors, the antibody can be polyclonal or monoclonal, natural or recombinant. Well-known protocols suitable for antibody production, purification and use can be found in, for example, Coligan et al., CURRENT PROTOCOLS IN IMMUNOLOGY (John Wiley & Sons NY, 1991-1994) Chapter 2 and Harlow, E. & Lane, D. Antibodies: A Laboratory Manual, Cold Spring Harbor, Cold Spring Harbor Laboratory, 1988, which are incorporated herein by reference.

[0131] Typically, the antibody of the present invention is combined or conjugated with an isolated protein, fragment, variant or derivative of a marker. For example, the antibody can be a polyclonal antibody. Such antibodies can be prepared, for example, by injecting an isolated protein, fragment, variant or derivative of a marker protein product into a production species (which may include mice or rabbits) to obtain a polyclonal antiserum. Methods for producing polyclonal antibodies are well known to those skilled in the art. Exemplary schemes that can be used are described in, for example, Coligan et al., CURRENT PROTOCOLS IN IMMUNOLOGY, supra, and Harlow & Lane, 1988, supra.

[0132] Monoclonal antibodies can be isolated using standard methods (e.g. & Milstein, 1975, Nature 256, 495, which is incorporated herein by reference) or by a more recent modification thereof (e.g., described in Coligan et al., CURRENT PROTOCOLS IN IMMUNOLOGY, supra), by immortalizing spleen or other antibody-producing cells derived from a producing species that has been inoculated with one or more isolated marker protein products and / or fragments, variants and / or derivatives thereof.

[0133] Typically, the inhibitory activity of a candidate inhibitor antibody can be assessed by in vitro and / or in vivo assays that detect or measure the expression level and / or activity of a marker protein in the presence of the antibody.

[0134] In some embodiments, modulators such as inhibitors can be rationally designed. These methods may include structural analysis of markers, and the design and / or construction of molecules that bind to, interact with, or otherwise modulate marker activity. These methods may particularly include computer-assisted three-dimensional modeling of the interaction between candidate modulators and markers.

[0135] In other embodiments, the modulator is, for example, a small organic molecule inhibitor, which may involve screening large compound libraries, numbering hundreds of thousands to millions of candidate inhibitors (compounds, including synthetic organic small molecules or natural products, such as inhibitory peptides or proteins), which can be screened or tested for their biological activity on any of hundreds of molecular targets in order to find potential new drugs or lead compounds. Screening methods may include, but are not limited to, computer-based ("in silico") screening and high-throughput screening based on in vitro assays.

[0136] Typically, active compounds or "hits" from this initial screening process are then sequentially tested through a series of other in vitro and / or in vivo tests to further characterize the active compounds. A progressively smaller number of "successful" compounds at each stage are selected for subsequent testing, ultimately leading to the selection of one or more candidate drugs for testing in human clinical trials.

[0137] At the clinical level, screening for candidate agents may include obtaining samples from a test subject before and after the subject is exposed to a test compound. The level of the marker protein in the sample (e.g., exosome sample) may then be measured and analyzed to determine whether the level and / or activity of the marker protein changes after exposure to the candidate agent. For example, the level of the protein product in the sample may be determined by mass spectrometry, Western blot, ELISA, electrochemistry, and / or by any other appropriate means known to those skilled in the art.

[0138] In this regard, candidate agents identified as being capable of reducing, eliminating, suppressing or inhibiting the expression level and / or activity of the marker can then be administered to patients with cancer. For example, if increased activity of a biomarker is at least partially responsible for the development and / or onset of cancer, administration of a candidate agent that inhibits or reduces the activity and / or expression of the marker can treat the cancer and / or reduce the risk of cancer.

[0139] With respect to the foregoing aspects, the term "subject" includes, but is not limited to, mammals, including humans, performance animals (eg, horses, camels, greyhounds), livestock (eg, cattle, sheep, horses), and companion animals (eg, cats and dogs). Preferably, the subject is a human.

[0140] All computer programs, algorithms, patents and scientific literature mentioned herein are incorporated by reference.

[0141] For the present invention, the database accession numbers or unique identifiers for genes or proteins provided herein (such as those shown in Tables 1 and 2) and the gene and / or protein sequences associated therewith are incorporated herein by reference.

[0142] So that preferred embodiments of the present invention can be fully understood and put into practical use, reference is made to the following non-limiting examples.

[0143] Example

[0144] Recent data suggest that tumor hypoxia is a powerful driver of secretion of factors that promote metastatic dissemination 8,9 A key component of secreted factors thought to be involved in enhancing metastasis is the release of exosomes. Accumulating evidence suggests that the rich array of proteomic and genomic information carried by tumor-derived exosomes is a novel mechanism by which cancer cells alter the surrounding stroma and malignant cell behavior. 10 Exosomes can affect the role of new blood vessels 11 , immunosuppression 12 signaling processes that induce drug resistance and oncogenic metastasis 13-15 Furthermore, the ability of exosomes to induce systemic changes is thought to promote metastatic dissemination, which is responsible for the majority of patient deaths. 16 .

[0145] Exosomes have also been reported to transfer oncogenic proteins 14 Exosome transfer in glioma cells has recently been shown to enhance tumorigenesis by delivering mutant epidermal growth factor receptor (EGFRvIII) isoforms, leading to increased expression of anti-apoptotic genes and enhanced proliferation. 14Similarly, colon cancer cells with a mutant form of KRAS were able to enhance the three-dimensional growth of wild-type KRAS colon cells by transferring mutant KRAS to wild-type cells using exosomes. Furthermore, non-metastatic melanoma cells could be induced to become more metastatic by taking up exosomes derived from a highly metastatic melanoma cell line. 17 However, whether this change in metastatic likelihood is permanent remains unclear.

[0146] The protein and RNA content of exosomes typically varies significantly depending on the cell type, tissue, and microenvironment from which they originate. Therefore, cancer-secreted exosomes and their molecular contents represent a potential source of biomarkers and therapeutic targets in cancer. Therefore, the overall goal of this example is to establish a means to non-invasively predict disease progression in NSCLC patients from blood using exosomes.

[0147] Currently, there is a large unmet need for the development of non-invasive and informative diagnostic markers for various solid malignancies. The proteomic and RNA information contained in tumor-derived exosomes has attracted significant attention regarding the use of exosomes as a non-invasive diagnostic tool. Since the technology for exosome isolation is now established and because exosomes are stable in body fluids including serum, urine, and saliva, they show great potential as reliable biomarkers for disease development. 23 Given that exosomes can provide molecular signatures of their cell of origin, proteomic and RNA analysis may also provide an effective means for identifying oncogenic mutations. Recently, studies have shown that exosome-based proteins (in this case the presence of glypican-1) can predict short-term disease-free survival in pancreatic cancer patients. 24 .

[0148] Furthermore, patient-derived exosomes have been shown to be useful for understanding disease progression and treatment options. This has been demonstrated with exosomes isolated from melanoma patients, which exhibited high protein content and elevated expression of TYRP2, VLA 4, and HSP70, proteins that are enriched in patients with a poor prognosis. 16 In addition, many different groups have identified retrotransposon RNA transcripts, single-stranded DNA (ssDNA), mitochondrial DNA, and oncogene amplifications (i.e., cMyc) in microvesicles and double-stranded DNA (dsDNA) in exosomes. 25 Among the oncogenes in exosomes, cMet (melanoma) 16 , mutant KRAS, and p53 in pancreatic cancer 26Therefore, given the presence of these specific exosomal biomolecules and their known release by tumor cells, exosomes may prove to be clinically useful enrichment templates for single or multiplex diagnostic biomarkers. 27 ,Depend on 28 Overview.

[0149] Materials and methods

[0150] Cell lines and cell culture

[0151] Human non-small cell lung cancer (NSCLC) cell lines were purchased from the American Type Culture Collection (ATCC). All cell lines were confirmed by short tandem repeat (STR) analysis and found to be negative for mycoplasma. All cells were maintained in a 37°C humidified incubator containing 5% CO2. SKMES1 cells were cultured in DMEM supplemented with 10% FBS (Gibco, Thermo Fisher Scientific) and penicillin-streptomycin. All other cells were cultured in RPMI supplemented with 10% FBS and penicillin-streptomycin. For hypoxia experiments, cells were cultured in a 37°C humidified incubator containing 2% O2 and 5% CO2.

[0152] Exosome isolation

[0153] Serum medium was removed by washing cells twice with PBS and replacing with 15 mL of serum-free medium. The medium was conditioned under normoxic (21% O2) or hypoxic (21% O2) conditions for 24 h. The conditioned medium was aliquoted into falcon tubes and floating cells and debris were removed by centrifugation at 300 × g for 10 min at 4 °C. The resulting supernatant was filtered through a 0.22 μm filter to remove remaining large particles. The clarified conditioned medium was concentrated to 300-500 μL at 3,500 g at 4 °C using a Centricon Plus-70 centrifugal filter (Ultracel-PL membrane, 100 kDa) device. The OptiPrep TM Density gradient purification of exosomes. The concentrated culture medium was overlaid on a discontinuous iodixanol gradient and centrifuged at 100,000 g at 4 °C. avg (k factor: 277.5) and centrifuged for 16 h. The exosome-containing fraction was identified using tunable resistive pulse sensing (TRPS), diluted to 20 mL in PBS, and centrifuged at 100,000 g at 4 °C. avg Centrifuge for 2 hours and resuspend the resulting pellet in PBS for further analysis.

[0154] Electron microscopy

[0155] Exosomes were visualized using a transmission electron microscope (TEM). 3 μL of exosome suspension was fixed in 50-100 μL of 2% paraformaldehyde. A 2-microliter aliquot was then transferred to each of two electron microscope grids coated with Formvar-carbon and then covered for 20 minutes. The grids were washed and transferred to 50 μL of uranyl oxalate solution at a pH of 7 for 5 minutes, and then transferred to 50 μL of methylcellulose-UA drops (a mixture of 4% uranyl acetate and 2% methylcellulose in a ratio of 100 μL / 900 μL) on ice for 10 minutes. The grids were removed and dried, and then observed at 80 kV using a JEM 1,011 transmission electron microscope.

[0156] Tunable Resistive Pulse Sensing (TRPS)

[0157] Exosome concentration and size were analyzed using TRPS (qNano, Izon Science Ltd) using an NP100 nanopore at 45 mm tension. Exosome concentration and size were normalized using a multipressure calibration with 70 nm carboxylated polystyrene beads of known concentration.

[0158] Western blotting

[0159] The following antibodies were used for Western blotting: TSG101 (Santa Cruz, sc-6037), CD63 (Abcam, ab8219), lipid valve structural protein 1 (BD Transduction Laboratories, 610821), HSP70 (Transduction Laboratories, 610608), calnexin (Cell Signaling Technology, 2679S), VCP (Abcam, ab11433), GANAB (Abcam, ab179805). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from ThermoScientific. The samples were lysed in reducing sample buffer [0.25M Tris-HCl (pH 6.8), 40% glycerol, 8% SDS, 5% 2-mercaptoethanol and 0.04% bromophenol blue] or non-reducing sample buffer (without 2-mercaptoethanol) and boiled at 95°C for 10 minutes. Proteins were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes, blocked in PBS-T (0.5% Tween-20) containing 5% skim milk powder, and probed with antibodies. Proteins were detected using X-ray film and enhanced chemiluminescence reagents (Amersham ECL Select).

[0160] ELISA

[0161] Duoset ELISA was purchased from R&D systems and used according to the manufacturer's instructions. Briefly, the capture antibody was diluted to a working concentration in PBS and placed in a 96-well microplate overnight at room temperature. The capture antibody was then removed and the plate was washed three times with wash buffer. The plate was then blocked with reagent diluent for 2 hours and then washed three times with wash buffer. The standards and samples were then incubated in the plate for 2 hours and then washed as before. The plate was then incubated with the detection antibody for 2 hours and then washed as before. Streptavidin-HRP was then added for 20 minutes and the plate was subsequently washed again. The color was developed by adding substrate solution for 20 minutes and the reaction was then stopped by adding stop solution. The optical density of each well was measured using a microplate reader set at 450 nm and a wavelength calibration of 540 nm.

[0162] TNC ELISA kit was purchased from RayBiotech and used according to the manufacturer's instructions.

[0163] plasma

[0164] Plasma was thawed on ice and centrifuged at 1,500 g for 10 min at 4 °C. The supernatant was removed and large vesicles were further removed with another centrifugation step at 10,000 g for 20 min at 4 °C. 500 μL was then overlaid on a qEV size exclusion column (Izon) followed by elution with PBS. Exosome positive fractions were pooled and Concentrate in an Ultra-4 10 kDa centrifugal filter unit to a final volume of 50-100 μL.

[0165] Mass spectrometry

[0166] Proteins from disrupted exosomes were proteolytically digested and analyzed on a LTQ-OrbitrapElite instrument coupled to a Waters NanoAcquity ultrahigh pressure liquid chromatograph. The number of discrete proteins identifiable within different exosomes on a quantitative basis was processed by a number of purpose-built software packages.

[0167] Statistical analysis

[0168] GraphPad Prism version 6.0 and MedCalc version 16.8.4 were used for all calculations. Unpaired Student's t-test was used to calculate the differences in expression values ​​of proteins from exosomes. Receiver operator characteristic (ROC) curves were used to determine the sensitivity and specificity of the predictive values. The Youden index was used to select the threshold. Univariate analysis using the log-rank test was used to assess disease-free survival (Kaplan-Meier curve).

[0169] result

[0170] This study is the first to demonstrate that exosomes are secreted by NSCLC cell lines H358, SKMES1, H23, and H1975. Figure 1 a shows the presence of classical exosomal proteins and the absence of the endoplasmic reticulum protein calnexin in exosomes isolated using the above protocol. In addition, the isolated exosomes showed the expected morphology and size distribution consistent with pure exosome preparations ( Figure 1 b and 2a).

[0171] These NSCLC cell lines were then cultured under hypoxic conditions and the effects on exosome secretion were monitored. Figure 1 As can be observed in c, 1d and 2a, hypoxic conditions induced the secretion of exosomes from each of the four cell lines studied, but the range of exosome size and morphology was not altered.

[0172] This study then sought to determine whether hypoxia altered the protein content or signature of exosomes secreted by NSCLC cell lines. Quantitative mass spectrometry demonstrated that exosomes from H358 and SKMES-1 cell lines had 83 and 156 upregulated proteins, respectively, under hypoxia, of which a total of 55 upregulated proteins were common to both cell lines ( Figure 2 b, Table 1). This study then sought to validate this mass spectrometry data. To this end, two upregulated proteins identified by mass spectrometry, namely neutral α-glucosidase AB (GANAB) and transitional endoplasmic reticulum ATPase (VCP), were analyzed by Western blotting and ELISA ( Figure 2 c and 2d) were confirmed to be upregulated in hypoxic exosomes from four NSCLC cell lines, supporting the mass spectrometry data.

[0173] This study then sought to determine whether upregulation of these proteins under hypoxic conditions is associated with patient disease progression in NSCLC. Figure 3 As can be seen in a, exosomes isolated from the plasma of NSCLC patients showed a typical size range and morphology. Western blotting then confirmed that hypoxic exosomal protein markers of GANAB, VCP, galectin-3 binding protein, TNC, and PMSA2 were significantly upregulated in NSCLC patients with a poor prognosis (i.e., those that developed or relapsed within the first 12 months after treatment) ( Figure 3 c). Figure 3 The ROC curve in d further demonstrated that the combined protein signature of GANAB, VCP, and galectin-3-binding protein had a high overall accuracy in identifying NSCLC patients with a poor prognosis. Figure 3 e support, Figure 3e showed that NSCLC patients with upregulated exosome expression of at least two of these markers, GANAB, VCP, and galectin-3 binding protein, showed significantly shorter disease-free survival compared with patients with only one or none of these markers highly expressed in their exosomes.

[0174] In addition to the exosomal protein markers of GANAB, VCP, and galectin-3-binding protein, other proteins from the original 55 hypoxia protein markers identified in NSCLC cell lines may also have prognostic value. Figure 4 showed that tenascin C (TNC) protein levels were also upregulated in the exosomes of NSCLC patients who were more likely to progress after treatment. Figure 4 The ROC curve in shows that it exhibits a fairly high accuracy in identifying NSCLC patients with a poor prognosis.

[0175] Figure 5 Provides information about Figure 3 Individual protein ROC and survival curves of the data for patient exosomal proteins GANAB, VCP, and Galectin-3-binding protein (MAC2BP) shown in d and 3e. The data demonstrate that, even on their own, each of these 3 proteins is an accurate prognostic marker for disease progression in NSCLC patients.

[0176] in conclusion

[0177] These data suggest that the above protein markers identified in hypoxic exosomes in vitro represent potential prognostic biomarkers for disease progression or recurrence in NSCLC cancer patients. Therefore, such exosomal biomarkers may represent reliable and non-invasive prognostic markers for a variety of solid malignancies.

[0178] Table 1 - Upregulated proteins in common between UH358 and SKMES-1 cell lines.

[0179]

[0180]

[0181] References

[0182] 1. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW, Jr. Cigarette smoking and changes in the histopathology of lung cancer [see annotation]. J Natl Cancer Inst 1997;89:1580-6.

[0183] 2. Mathers C, Vos T. The burden of disease and injury in Australia-summary report. Canberra: Australian Institute of Health and Welfare ISBN 1 74024 022 7; 1999.

[0184] 3. Larsen JE, Pavey SJ, Bowman R, et al. Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J 2007;30:21-5.

[0185] 4. Larsen JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007;28:760-6.

[0186] 5. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007;13:2946-54.

[0187] 6. S ELA, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:347-57.

[0188] 7. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology 2007;9:654-9.

[0189] 8. Sceneay J, Chow MT, Chen A, et al. Primary tumor hypoxia recruits CD11b+ / Ly6Cmed / Ly6G+immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012;72:3906-11.

[0190] 9. Chafe SC, Lou Y, Sceneay J, et al. Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of ametastatic niche by stimulating G-CSF production. Cancer Res 2015;75:996-1008.

[0191] 10.Martins VR, Dias MS, Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol 2013;25:66-75.

[0192] 11. Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci US A 2013;110:7312-7.

[0193] 12. Xiang X, Poliakov A, Liu C, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124: 2621-33.

[0194] 13. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrineVEGF upon the uptake of tumor-derived microvesicles containing oncogenicEGFR. Proc Natl Acad Sci USA 2009;106:3794-9.

[0195] 14. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-24.

[0196] 15. Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes incountering trastuzumab-based therapy. J Cell Physiol 2012;227:658-67.

[0197] 16.Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine 2012;18:883-91.

[0198] 17. Demory Beckler M, Higginbotham JN, Franklin JL, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 2013;12:343-55.

[0199] 18. Corcoran C, Rani S, O'Brien K, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012;7:e50999.

[0200] 19. Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 2009;125:1595-603.

[0201] 20. Lv LH, Wan YL, Lin Y, et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J Biol Chem 2012;287:15874-85.

[0202] 21. Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011;16:1-12.

[0203] 22. Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4:1595-604.

[0204] 23. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012;1820:940-8.

[0205] 24. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015;523:177-82.

[0206] 25. Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell research 2014;24:766-9.

[0207] 26. Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 2014;289:3869-75.

[0208] 27. Roberson CD, Atay S, Gercel-Taylor C, Taylor DD. Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer biomarkers: section A of Disease markers 2010;8:281-91.

[0209] 28.Zocco D, Ferruzzi P, Cappello F, Kuo WP, Fais S. Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Frontiers in oncology 2014;4:267.

[0210] 29. Wen SW, Everitt SJ, Bedo J, et al. Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. PLoS One 2015;10:e0142608.

[0211] 30. Lobb RJ, Becker M, Wen SW, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. Journal of extracellular vesicles 2015;4:27031.

[0212] Example 2

[0213] Despite significant treatment advances, lung cancer remains the leading cause of cancer-related deaths worldwide 1 The overall five-year survival rate for patients with non-small cell lung cancer (NSCLC) is very poor, as low as 15%. 2 Biopsy is used to diagnose and subtype NSCLC, and TNM staging is the most important factor in predicting survival and guiding clinical intervention. 2 . However, despite curative intent treatment with surgery-radiation or chemoradiation, a large proportion of patients with early-stage and locally limited NSCLC suffer from treatment-refractory disease or develop metastatic disease, suggesting that TNM staging alone is insufficient to guide disease management. Therefore, there is a significant unmet clinical need to identify these patients who respond poorly to current treatments and allow for tailored therapeutic interventions. Prognostic biomarkers, particularly non-invasive liquid biomarkers, may allow clinicians to stratify patients who require intensive treatment or adjuvant therapeutic interventions.

[0214] Small extracellular vesicles called exosomes have been shown to be a non-invasive way to identify pancreatic cancer outcomes 3 Exosomes are secreted membrane-enclosed vesicles with a diameter range of 30-150 nm. 4 Originating from inward budding of multivesicular bodies, exosomes contain a variety of nucleic acids, lipids, and proteins derived from their cell of origin 4 After fusion with the plasma membrane, exosomes are released into the extracellular environment and are able to enter the circulation 4 . It is for this reason that the isolation of exosomes from patient fluids represents a potential source of new markers that can be used to characterize NSCLC in greater detail compared to current clinical techniques.

[0215] It is well established that hypoxia occurs early in tumor development and causes aggressive, invasive, and metastatic phenotypes 5,6We hypothesized that NSCLC cells exposed to hypoxia would secrete exosomes with distinct proteomic profiles, indicative of an aggressive phenotype of the cell of origin. To address the question of whether hypoxia induces changes in exosome protein content, we isolated exosomes secreted by human NSCLC cell lines (H358, SKMES1, H23, and H1975) cultured under normoxic (21% O2) or hypoxic (2% O2) conditions using known methods. Figure 6 A and B and Fig.10 ) 7,8 When measured by tunable resistive pulse sensing (TRPS), exosomes showed a typical size distribution and contained the classical exosomal markers HSP70, FLOT1, and CD63 ( Figure 6 B; Fig.10 Interestingly, transmission electron microscopy (TEM) and TRPS nanoparticle analysis revealed that NSCLC cells significantly increased exosome secretion in response to hypoxia ( Figure 6 A and B; Fig.10 B). The proteome of normoxic and hypoxic exosomes from adenocarcinoma H358 and squamous cell carcinoma SKMES1 cells was evaluated using mass spectrometry. Label-free quantification by spectral counting identified 32 proteins (16 cytoplasmic, 10 secreted, and 6 transmembrane) that were upregulated in both H358 and SKMES1 exosomes under low oxygen tension ( Figure 6 C; Tables 2 and 3). Five of these proteins (two cytoplasmic [VCP 9 , PSMA2 10 ], 2 secretory types [TNC 11,12 ,THBS1 13 ] and a transmembrane protein [MAC2BP 14 ]). All five proteins were confirmed to be contained at higher abundance in exosomes from additional hypoxic NSCLC cell lines ( Figure 6 D and E).

[0216] We then hypothesized that hypoxia-induced exosome changes could be used as prognostic biomarkers for disease progression in early-stage NSCLC. Exosomes were isolated from plasma of a 32-patient discovery cohort of treatment-naïve stage I-III NSCLC sampled at diagnosis ( Figure 7 A and B). Although hypoxia increases exosome secretion in NSCLC cells ( Fig.10 B), but we were surprised to find that the plasma exosome concentration of NSCLC patients as a categorical variable had no prognostic value for clinical recurrence within 18 months ( Figure 7C). Interestingly, the combined 5-protein exosome marker (VCP, MAC2BP, TNC, PSMA2, and THBS1) was specifically increased in exosomes from relapsed NSCLC subjects ( Figure 7 D). Each protein from the exosome signature is an excellent prognostic biomarker for disease recurrence ( Fig.11 Interestingly, we were able to generate a clear separation in disease-free survival (DFS) of patients based on the abundance of these 5 exosomal proteins exceeding the Youden threshold (≤2 = no relapse; ≥3 = relapse) ( Figure 7 F and G). Importantly, the receiver operating characteristic (ROC) curve showed that these 5 exosomal proteins had the ability to predict disease development with 100% specificity and sensitivity within this discovery panel ( Figure 7 F). In addition, exosomal signatures were able to distinguish the overall survival (OS) of patients in the discovery group ( Figure 7 I), indicating that both relapse and OS were associated with the abundance of exosomal markers.

[0217] Based on the prognostic value of exosome signature, we investigated the potential mechanisms supporting this exosome signature. We recently demonstrated that the protein content of exosomes can reflect the phenotype of the cell of origin. 15 We performed gene set enrichment analysis (GSEA) of total protein abundance in exosomes derived from normoxic or hypoxic conditions. Many gene sets were significantly enriched in exosomes from NSCLC cells isolated under hypoxia ( Fig.12 ), including glycolysis, MYC targets, E2F targets, and xenobiotic metabolism. Interestingly, the highest ranked gene sets enriched in hypoxic exosomes were associated with EMT ( Figure 8 A; Fig.12 A) Given that hypoxia is a strong inducer of EMT in cancer cells 16 We hypothesized that the mesenchymal phenotype alone was sufficient to induce secretion of exosomal markers. To determine whether the five exosomal proteins were secreted by normal or transformed lung epithelial cells, we isolated exosomes from an isogenic human bronchial epithelial cell (HBEC) line. Strikingly, p53 knockdown, Kras v12 overexpression, and LKB1 knockdown (30KT) significantly inhibited the secretion of exosomal markers. p53 / KRAS / LKB1 ) 17 undergoing oncogenic-induced EMT ( Figure 8 B and C) HBEC can secrete elevated exosome marker proteins even under normoxic conditions ( Figure 8D and E). To validate the association of mesenchymal lung cancer cells secreting exosome markers, we then analyzed E-cadherin expression in patient tumor biopsies from the discovery cohort. Immunohistochemistry of tumor biopsies showed that E-cadherin expression was not associated with exosome marker scores ≤2 ( Figure 8 There was a significant association between decreased E-cadherin expression in tumors of patients with high exosome signature scores ≥ 3 compared with patients with high exosome signature scores (R 2 =0.458, p<0.001)( Fig.13 ). These data support the notion that EMT in neoplastically transformed lung cells is responsible for the elevated protein levels found in our in vitro and in vivo exosome signatures in NSCLC patients.

[0218] Depolarizing the epithelial cell phenotype to an elongated mesenchymal cell type not only promotes the invasive and metastatic phenotype of cancer cells but also promotes chemoresistance 17,18 Therefore, for independent validation, we evaluated 20 subjects with locally advanced NSCLC who received standard-of-care chemoradiation consisting of conformal RT (60 Gy / 30 fractions, 6 weeks) and concomitant chemotherapy (cisplatin / etoposide or carboplatin / paclitaxel). 18 Patients were monitored with F-FDG PET / CT and standard CT scans every three months for 12 months and then every six months ( Fig. 9 A and B; Table 5). Exosome concentrations were measured at baseline using TRPS. There were no significant differences in circulating exosome abundance between subjects who relapsed within 18 months ( Fig. 9 C). Consistent with the discovery group, exosomal protein signatures showed significant elevation and prognostic value in subjects who relapsed within 18 months compared with subjects who did not relapse within 18 months ( Fig. 9 D; Fig.14 Using the same thresholds and algorithms established in the discovery cohort (≤2 markers = low risk of recurrence within 18 months; ≥3 = high risk of recurrence within 18 months), the signature clearly distinguished patients who recurred within 18 months from those who recurred after 18 months ( Fig. 9 D and E). ROC curve analysis further confirmed the specificity and sensitivity of exosome markers for disease recurrence ( Fig. 9 F). Further consistent with the discovery group, exosomal signatures can differentiate patients based on OS, suggesting that exosomal protein signatures are ideal classifiers for subjects who relapse early and have poor overall survival.

[0219] Considering the association of EMT with metastasis and chemoresistance 16-20These data identify a mechanism for the very short disease-free survival in both groups of NSCLC patients in this study. This work suggests that hypoxia / EMT-related exosomal biomarkers are very promising for identifying early-stage NSCLC patients at risk for early recurrence and poor clinical outcomes. Hypoxia has multiple functions in promoting tumor growth and metastasis 5,6,21 , including the developmental EMT program 16 , thereby promoting the metastasis and chemoresistance of cancer cells 16-20,22 . Importantly, the ability to non-invasively and reliably detect hypoxia and / or EMT in NSCLC could serve as a potential prognostic screening tool in early-stage NSCLC, thereby facilitating curative treatment and reducing overall mortality. Our results provide strong preliminary evidence for the newly discovered exosomal protein signature as a marker of NSCLC disease progression. Further work will be conducted to determine whether the exosomal signature is a predictive biomarker in the chemoradiation setting, or whether the exosomal signature is a prognostic biomarker in the general NSCLC setting. Although TNM staging provides significant benefits in patient management and will remain key to the clinical management of NSCLC patients, exosomal signatures have the potential to complement TNM staging and allow for specific tailoring of therapeutic interventions to improve clinical outcomes.

[0220] Materials and methods

[0221] Cell culture

[0222] Human non-small cell lung cancer (NSCLC) cell lines (adenocarcinoma and squamous cell carcinoma) H358, SKMES1, H23, and H1975 were purchased from ATCC. Cell line authentication was performed using short tandem repeat profiling. NSCLC were maintained in DMEM or RPMI supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 mg / mL streptomycin and incubated at 37°C in 5% CO2. Isogenic normal human bronchial epithelial cells (HBEC) were a gift from Dr. Jill Larsen 19,23 HBEC were cultured at 37°C and 5% CO2 in keratinocyte serum-free medium (KSFM) supplemented with EGF (5 μg / L) and bovine pituitary extract (50 mg / L). Cell-conditioned medium (CCM) from NSCLC cell lines was collected from cells cultured in serum-free medium under normoxic (21% O2) or hypoxic (2% O2) conditions. avg CCM was collected by overnight centrifugation from HBEC cells conditioned under normoxic or hypoxic conditions in KSFM depleted of bovine exosomes.

[0223] Antibodies and reagents

[0224] The following antibodies were used for western blotting: calnexin (Cell Signaling Technology, 2679S), CD9 (Abcam, ab92726), CD63 (Abcam, ab8219), lipid valve structural protein 1 (BD Transduction Laboratories, 610821), HSP70 (Transduction Laboratories, 610608), TSG101 (Santa Cruz, sc-6037), VCP (Abcam, ab11433). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from ThermoScientific. MAC2BP, PSMA2 and THBS1 ELISA DuoSets were purchased from R&D Systems, and TNC ELISA kits were purchased from Abcam. qEV columns were purchased from Izon and stored in PBS (0.1% sodium azide) at 4°C. OptiPrep TM Purchased from Sigma-Aldrich. qPCR was performed as previously described 24 .

[0225] patient

[0226] The independent validation group included 20 patients who provided informed consent to participate in an ERB-approved prospective trial of sequential FDG PET / CT before, during, and after curative intent chemoradiation. As previously reported, eligibility for the trial included an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 25 Staging of Stage I-III NSCLC 18 F-FDG PET / CT, histological or cytological confirmation. Exclusion criteria included previous thoracic radiotherapy and complete surgical tumor resection. Patients received concurrent chemoradiotherapy according to two standardized regimens. RT consisted of 60 Gy / 30 fractions over 6 weeks. One of the following two chemotherapy regimens was administered: carboplatin [area under the curve, 2, intravenous] and paclitaxel [45 mg / m2, intravenous] once a week for elderly patients or those with significant comorbidities; or cisplatin [50 mg / m2, intravenous] on days 1, 8, 29, and 36, and etoposide [50 mg / m2, intravenous] on weeks 1 and 5 for young suitable patients. Data were obtained at baseline, day 10, day 24, and day 90. 18 F-FDG PET / CT scan. Ongoing monitoring with standard CT imaging will be performed every three months for 12 months and every six months thereafter.

[0227] Exosome isolation and analysis

[0228] Exosomes were isolated and analyzed as previously described. 7,17,26 For exosome isolation from in vitro cell culture, CCM was centrifuged at 300 g for 10 min at 4 °C and filtered through a 0.22 μm filter to remove floating cells and large extracellular vesicles. The clarified CCM was then concentrated to 500 μL and overlaid on a discontinuous iodixanol density gradient and centrifuged at 100,000 g at 4 °C. avg Centrifuge for 16 h. Dilute the exosome-containing fraction to 20 mL in PBS and centrifuge at 100,000 g at 4 °C. avg The pellet was resuspended in PBS and stored at -80 °C until use. To isolate exosomes from human plasma, 3 mL of plasma was thawed at room temperature and prepared by centrifugation at 1,500 g and 10,000 g for 10 and 20 min, respectively, to remove remaining platelets and large vesicles. The prepared plasma was then diluted to 20 mL in PBS containing 2 mM EDTA and centrifuged at 100,000 g at 4 °C. avg Centrifuge for 2 hours. Resuspend the resulting pellet in 500 μL PBS and overlay on a size exclusion column, which is then eluted with PBS. Collect the exosome-containing fractions and use Ultra-4 10kDA nominal molecular weight centrifugal filter units were concentrated to 100 μL. The concentrated exosomes were stored at -80 °C until use. Exosome isolation from cell culture and human plasma was confirmed by Western blotting, tunable resistive pulse sensing (TRPS), and transmission electron microscopy as described previously. 7,17,26 .

[0229] Western blot analysis

[0230] Western blotting was performed as described previously 7,24 . Briefly, proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, blocked in PBS-T (0.5% Tween-20) containing 5% nonfat dry milk, and probed with antibodies. Protein bands were detected with enhanced chemiluminescence reagent (Amersham ECL Select). Protein bands were quantified using ImageJ and normalized to a loading control. To control for variability between gels, patient VCP levels were calibrated against 5 μg of hypoxia-derived SKMES1 exosomes from the same gel before normalization to lipid valve structural protein 1 as a loading control.

[0231] Immunohistochemistry

[0232] IHC analysis was performed on formalin-fixed paraffin-embedded (FFPE) samples using automated staining and optimized methods. To assess the expression of E-cadherin within tumor cells, the staining intensity of immunostained tumor cells was scored as follows: 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong).

[0233] Mass spectrometry

[0234] Exosome preparations were reduced by adding 10 mM dithiothreitol (1 hour at 4°C, 2 hours at 22°C) in the presence of 2% SDS, protease inhibitors (Sigma Aldrich, P8340) and 50 mM Tris.HCl pH 8.8. The samples were then alkylated by adding iodoacetamide to 25 mM (1 hour at 22°C) and co-precipitated with methanol overnight at -20°C using trypsin (1:100 enzyme:substrate). The pellet was resuspended in 10% acetonitrile, 40 mM ammonium bicarbonate and digested at 37°C for 8 hours by adding additional trypsin (1:100 enzyme:substrate) after 2 hours.

[0235] LCMS analysis of the acidified digest (trifluoroacetic acid) was performed by connecting a NanoAcquity UPLC (Waters) in front of an Elite Orbitrap ETD mass spectrometer (Thermo Fisher Scientific). 2 micrograms of the digest was loaded onto a 20 mm x 180 μm Symmetry C18 trap (Waters) and separated over 120 minutes on a 200 mm x 75 μm, BEH130 1.7 μm column (Waters) using the following series of linear gradients (buffer A: 0.1% formic acid in water; buffer B: 0.1% formic acid in acetonitrile): 2% B to 5% B over 5 minutes, 30% B over 75 minutes, 50% B over 10 minutes, 95% B over 5 minutes, and hold for 6 minutes, re-equilibrate in 2% B. The eluent from the column was introduced into the mass spectrometer via a 10 μm P200P coated silica emitter (New Objective) and a Nanospray-Flex source (Proxeon Biosystems A / S). Source voltage 1.8 kV, heated capillary temperature 275°C, MS acquired in the orbitrap at 120 000 resolution AGC 1E6 using the top15 method, MS2 in the ion trap AGC 1E4, 50 ms maximum injection time. The MS1 lock mass 445.120024 was used.

[0236] Using MaxQuant (version 1.4.1.2) 27Protein identification and label-free quantification were performed. MaxQuant was used to extract peak lists from Xcalibur raw files (Thermo Fisher Scientific, Germany), and the embedded database search engine Andromeda 28 For specifying peptide to spectrum matches (PSMs). The database searched consisted of the complete proteome of Homo sapiens (88,378 canonical sequences downloaded from www.uniprot.org, August 2013). Reverse sequences and the MaxQuant contaminant database were also searched. Label-free quantification was performed, the instrument type was set to Orbitrap, the precursor mass tolerance for the first search was set to 20 ppm, the precursor mass tolerance for the main search was set to 4.5 ppm, the fragment ion mass tolerance was set to 0.5 Da, the enzyme specificity was set to Trypsin / P, a maximum of two missed cleavages were allowed, carbamidomethylcysteine ​​was specified as a fixed modification, and acetylation of the protein N-terminus, deamidation of asparagine / glutamine, and oxidation of methionine were specified as variable modifications. Matching between the second peptide search and runs was enabled using default settings. For identification, the PSM and protein level FDR were set to 0.01. Default settings were applied to all other parameters. As previously described 29 , protein inference and label-free quantification by spectral counting (including normalization).

[0237] Gene set enrichment analysis

[0238] Gene set enrichment analysis (GSEA) 30 , version 2.2.3, was used to identify 15 Enriched pathways in exosomes isolated from hypoxic SKMES1 cells. Non-log2 transformed protein intensity values ​​of all proteins in exosomes derived from normoxic or hypoxic SKMES1 exosomes were analyzed using the Molecular Signatures Database (MSigDB). Analyses were performed using the Hallmark gene set database (version 5.2), the Signal2Noise ranking metric, 1000 gene set permutations, and weighted enrichment statistics. Results were considered significant with a false discovery rate (FDR) < 0.05.

[0239] Statistical analysis

[0240] GraphPad Prism version 6.0, EdgeR version 2.6.10 31, MedCalc version 16.8.4 and SPSS statistics were used for all calculations. Unpaired Student's t-test was used to calculate the difference in expression values ​​of proteins from in vitro exosomes. The Mann Whitney test was used in exosomes derived from patients. Negative binomial exact test was used to evaluate mass spectrometry-derived spectral counts, where the Benjamini-Hochberg adjustment was applied to control FDR. Receiver operating characteristic (ROC) curves were used to determine the sensitivity and specificity of prognostic values. The Youden index was used to select the threshold. Univariate analysis using the log-rank test was used to evaluate disease-free survival (Kaplan-Meier curve). Differences with p values ​​less than 0.05 were considered significant (*p<0.05, **p<0.01, ***p<0.001), except that the FDR thresholds for spectral counts and GSEA data were 0.001 and 0.05, respectively.

[0241] Throughout the specification, the purpose is to describe the preferred embodiments of the present invention, and the present invention is not limited to any one embodiment or a specific set of features. Therefore, it will be understood by those skilled in the art that, based on this disclosure, various modifications and changes can be made to the illustrated specific embodiments without departing from the scope of the present invention.

[0242] All computer programs, algorithms, patents and scientific literature mentioned herein are incorporated by reference.

[0243] Table 2 - Proteins commonly upregulated in NSCLC hypoxic exosomes List of proteins upregulated in H358 and SKMES1 hypoxic exosomes (FDR < 0.01%).

[0244]

[0245] Table 3 - Subcellular localization of proteins commonly upregulated in NSCLC hypoxic exosomes (FDR < 0.01%).

[0246]

[0247] Table 4 - Patient information of the discovery group.

[0248]

[0249] Table 5 - Patient information of the confirmation group.

[0250]

[0251] References

[0252] 1. Torre, LA, Bray, F., Siegel, RL, Ferlay, J., Lortet-Tieulent, J. & Jemal, A. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87-108 (2015).

[0253] 2. Molina, JR, Yang, P., Cassivi, SD, Schild, SE & Adjei, AA Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings 83, 584-594 (2008).

[0254] 3. Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177-182 (2015).

[0255] 4. Lobb, RJ, Lima, LG & Moller, A. Exosomes: Key mediators of metastasis and pre-metastatic niche formation. Seminars in cell & developmental biology (2017).

[0256] 5. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis reviews 26, 225-239 (2007).

[0257] 6. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93, 266-276 (2001).

[0258] 7. Lobb, RJ, Becker, M., Wen, SW, Wong, CS, Wiegmans, AP, Leimgruber, A., et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4, 27031 (2015).

[0259] 8. Lobb, R. & Moller, A. Size Exclusion Chromatography: A Simple and Reliable Method for Exosome Purification. Methods in molecular biology 1660, 105-110 (2017).

[0260] 9. Valle, CW, Min, T., Bodas, M., Mazur, S., Begum, S., Tang, D., et al. Critical role of VCP / p97 in thepathogenesis and progression of non-small cell lung carcinoma. PloS one 6, e29073 (2011).

[0261] 10. Denlinger, CE, Rundall, BK, Keller, MD & Jones, DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. The Annals ofthoracic surgery 78, 1207-1214; discussion 1207-1214 (2004).

[0262] 11. Tang, YA, Chen, CH, Sun, HS, Cheng, CP, Tseng, VS, Hsu, HS, et al. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic acids research 43, 1593-1608 (2015).

[0263] 12. Oskarsson, T., Acharyya, S., Zhang, XH, Vanharanta, S., Tavazoie, SF, Morris, PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature medicine 17, 867-874 (2011).

[0264] 13. Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer cell 15, 195-206 (2009).

[0265] 14. Marchetti, A., Tinari, N., Buttitta, F., Chella, A., Angeletti, C. A., Sacco, R., et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62, 2535-2539 (2002).

[0266] 15. Lobb, RJ, Hastie, ML, Norris, EL, van Amerongen, R., Gorman, JJ & Moller, A. Oncogenic transformation of lung cells results in distinct exosome protein profiles similar to the cell of origin. Proteomics (2017).

[0267] 16. Thiery, JP, Acloque, H., Huang, RY & Nieto, MA Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).

[0268] 17. Lobb, RJ, van Amerongen, R., Wiegmans, A., Ham, S., Larsen, JE & Moller, A. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. International journal of cancer (2017).

[0269] 18. Fischer, KR, Durrans, A., Lee, S., Sheng, J., Li, F., Wong, ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472-476 (2015).

[0270] 19. Larsen, JE, Nathan, V., Osborne, JK, Farrow, RK, Deb, D., Sullivan, JP, et al. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. The Journal of clinical investigation 126, 3219-3235 (2016).

[0271] 20. Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525-530 (2015).

[0272] 21. Sceneay, J., Chow, MT, Chen, A., Halse, HM, Wong, CSF, Andrews, DM, et al. Primary Tumor Hypoxia Recruits CD11b+ / Ly6Cmed / Ly6G+ImmuneSuppressor Cells and Compromises NK Cell Cytotoxicity in the PremetastaticNiche. Cancer Research 72, 3906 (2012).

[0273] 22. Kalluri, R. & Weinberg, RA The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 119, 1420-1428 (2009).

[0274] 23. Sato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66, 2116-2128 (2006).

[0275] 24. Lobb, RJ, van Amerongen, R., Wiegmans, A., Ham, S., Larsen, JE & Moller, A. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. International journal of cancer 141, 614-620 (2017).

[0276] 25. Everitt, SJ, Ball, DL, Hicks, RJ, Callahan, J., Plumridge, N., Collins, M., et al. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET / CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 55, 1069-1074 (2014).

[0277] 26. Wen, SW, Sceneay, J., Lima, LG, Wong, CS, Becker, M., Krumeich, S., et al. The biodistribution and immunesuppressive effects of breast cancer-derived exosomes. Cancer Research, canres.0868.2016 (2016).

[0278] 27. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification. Nature biotechnology 26, 1367-1372 (2008).

[0279] 28. Cox, J., Neuhauser, N., Michalski, A., Scheltema, RA, Olsen, JV & Mann, M. Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of proteome research 10, 1794-1805 (2011).

[0280] 29. Dave, KA, Norris, EL, Bukreyev, AA, Headlam, MJ, Buchholz, UJ, Singh, T., et al. A comprehensive proteomic view of responses of A549 type II alveolarepithelial cells to human respiratory syncytial virus infection. Molecular & cellular proteomics: MCP 13, 3250-3269 (2014).

[0281] 30. Subramanian, A., Tamayo, P., Mootha, VK, Mukherjee, S., Ebert, BL, Gillette, MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102, 15545-15550 (2005).

[0282] 31. Robinson, MD, McCarthy, DJ & Smyth, GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. (edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.) Bioinformatics 26, 139-140 (2010).

Claims

1. A method for determining the aggressiveness of cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or correlates with the aggressiveness level of the cancer.

2. A method for determining the prognosis of cancer in a subject, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2, and the expression level of the one or more markers indicates or is associated with a more unfavorable or more favorable prognosis for the cancer.

3. The method of claim 1 or claim 2, wherein a relatively decreased expression level of the one or more markers indicates or is associated with a more favorable prognosis and / or a less aggressive cancer; and / or a relatively increased expression level of the one or more markers indicates or is associated with a more unfavorable prognosis and / or a highly aggressive cancer.

4. The method of any one of the preceding claims, comprising the further step of diagnosing the subject with: (i) a highly aggressive cancer or a less aggressive cancer; and / or (ii) a more unfavorable prognosis or a more favorable prognosis.

5. The method of any one of the preceding claims, wherein the cancer prognosis or aggressiveness is used at least in part to determine the likelihood of cancer metastasis in the subject.

6. The method of claim 5, wherein a relatively decreased expression level of the one or more markers indicates or is associated with a decreased likelihood of cancer metastasis; and / or a relatively increased expression level of the one or more markers indicates or is associated with an increased likelihood of cancer metastasis.

7. A method for predicting the responsiveness of cancer in a subject to an anti-cancer treatment, the method comprising the step of determining the expression level of one or more markers in an exosome sample of the subject, wherein the markers comprise one or more of those proteins listed in Table 1 and / or Table 2, and the altered or modulated expression level of the one or more markers indicates or correlates with a relative increased or decreased responsiveness of the cancer to the anti-cancer treatment.

8. The method according to any one of the preceding claims, comprising the further step of treating the cancer in the subject.

9. A method of treating cancer in a subject, the method comprising the steps of: Determining the expression level of one or more markers in the exosome sample of the subject, wherein the markers include one or more of those proteins listed in Table 1 and / or Table 2 and based on the determination made, initiating, continuing, changing or interrupting anti-cancer therapy.

10. The method of any one of claims 7 to 9, wherein the anti-cancer treatment comprises administering to the subject a therapeutically effective amount of an anti-cancer agent that reduces the expression and / or activity of the one or more markers.

11. The method according to any one of claims 7 to 10, wherein the anti-cancer treatment comprises administering to the subject a therapeutically effective amount of an anti-cancer agent that prevents or inhibits metastasis of the cancer.

12. The method of claim 10 or claim 11, wherein the anti-cancer agent is an antibody or a small molecule.

13. The method according to any one of the preceding claims, further comprising the step of obtaining the exosome sample from the subject.

14. The method according to any one of the preceding claims, further comprising the step of comparing the expression level of the one or more markers in the exosome sample with a reference exosome expression level of the corresponding one or more markers.

15. The method of any one of the preceding claims, wherein the cancer is or comprises lung cancer.

16. The method of claim 15, wherein the lung cancer is or comprises non-small cell lung cancer.

17. A method of identifying or producing an agent for treating cancer in a subject, comprising the steps of: (a) contacting cells expressing the markers listed in Table 1 and / or Table 2 with a candidate agent; and (b) determining whether the candidate agent modulates the expression and / or activity of the marker.

18. The method of claim 17, wherein the candidate agent at least partially reduces, eliminates, suppresses or inhibits the expression and / or activity of the marker.

19. A medicament produced by the method of claim 17 or claim 18 for use in a method according to any one of claims 10 to 16.

20. The method according to any one of claims 1 to 18 or the medicament according to claim 19, wherein the one or more markers are selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, neutral alpha-glucosidase AB, 60 kDa heat shock protein, lysyl oxidase homolog 2, tenascin C, fatty acid synthase, agrin, aspartyl aminopeptidase, proteasome subunit alpha type-1, proteasome subunit alpha type-2, proteasome subunit alpha type-3, proteasome subunit alpha type-4, proteasome subunit alpha type-5, proteasome subunit alpha type-6, proteasome subunit beta type-1, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-2, proteasome subunit beta type-3, proteasome subunit beta type-4, proteasome subunit beta type-5, proteasome subunit beta type-6, proteasome subunit beta type-7, proteasome subunit beta type-8, thrombospondin-1, latent transforming growth factor beta binding protein 3, and any combination thereof.

21. The method or agent of claim 20, wherein the one or more markers are selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, thrombospondin-1, and any combination thereof.

22. The method or agent of claim 20, wherein the one or more markers are selected from the group consisting of: galectin-3-binding protein, transitional endoplasmic reticulum ATPase, tenascin C, proteasome subunit alpha type-2, neutral alpha-glucosidase AB, and any combination thereof.